Ann: Two PTX abstracts accepted at prestigious ISCT conference, page-3

Significant progress with the development of OmniCAR & CellPryme!


Prescient’s Senior Vice President of Scientific Affairs, Dr Rebecca Lim said,

“Prescient has made significant progress with the development of its cell therapy platforms, OmniCAR and CellPryme, which have the potential to advance the utility and utilization of cell therapies.

The ISCT meeting is a wonderful opportunity for us to showcase our OmniCAR and CellPryme data to an expert cell therapy audience of researchers, clinicians and pharmaceutical industry delegates.